Wire · opportunities
Antengene Starts Phase III CLINCH-3 Trial of ATG-022 in Advanced Gastric Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Antengene has initiated a pivotal Phase III trial (CLINCH-3) in China for ATG-022, an antibody-drug conjugate targeting advanced gastric cancer with moderate-to-high CLDN18.2 expression, following promising Phase I/II results and Breakthrough Therapy Designation from China's NMPA. The trial aims to expand regionally and support marketing approval.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your biotech drug targeting late-stage gastric cancer now has a faster path to market in China due to early-phase data and breakthrough status. Speed up trial site recruitment beyond China to speed approval and open up regional sales rapidly.
◆ Coverage
2 sources · 21 Sep 2026
◆ Related on Wire
◆ Topics